Immunobiology of chimeric antigen receptor-T (CAR-T) cells in cancer immunity
Chimeric antigen receptor-T (CAR-T) cell therapy has shown remarkable clinical benefits for various hematologic malignancies, but its translation to wider patient populations and solid tumors remains challenging due to immunobiological obstacles. A Research Topic aims to elucidate the cancer-relevant immunobiology that underpins CAR-T cell function, persistence, and safety.
CAR-T cell therapy has revolutionized cancer immunotherapy, providing significant benefits for hematologic malignancies. However, its application to broader patient populations and solid tumors is hindered by complex immunobiological challenges. Factors such as inadequate CAR-T cell trafficking, tumor antigen diversity, and immune escape contribute to variable efficacy. The tumor microenvironment and immune-related toxicities also pose significant obstacles. A Research Topic seeks to clarify the mechanisms underlying CAR-T cell function and determine therapeutic outcomes by assembling mechanistic studies, clinical investigations, and translational research. It will focus on CAR design, patient-specific immune context, and real-time functional states of T cells to optimize next-generation CAR engineering and combination therapies.
This content was automatically generated and/or translated by AI. It may contain inaccuracies. Please refer to the original sources for verification.